Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
NCT04195958 · Genentech, Inc. · PHASE4 · terminated · last registry update 2022-03-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to low enrollment, this study was terminated early.” | – | Registry record, Genentech, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-10Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab 120 mg + Ligelizumab 240 mg (NCT05678959)
- 2022-12-30Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580369)
- 2022-05-25Phase 3 first posted: Beijing Tongren Hospital, Mometasone furoate nasal spray hormone + Mometasone furoate nasal spray hormone + oral hormone (NCT05390255)
- 2021-11-22Results posted on the registry: University of Wisconsin, Madison, Omalizumab + Placebos (NCT02966314)
- 2021-08-27Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab (NCT05024058)
- 2021-08-24Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab + Placebo (NCT03437278)
- 2021-08-18Also stopped (withdrawn): Beth Israel Deaconess Medical Center, Omalizumab Injection [Xolair] (NCT04535817)
- 2021-08-02Phase 3 first posted: Novartis Pharmaceuticals, ligelizumab + Placebo (NCT04984876)
- 2021-07-26Phase 3 first posted: Teva Pharmaceuticals USA, TEV-45779 + XOLAIR® Injection (NCT04976192)
- 2021-07-13Results posted on the registry: University of California, Davis, Omalizumab + Placebo (NCT00367016)
- 2021-06-29Phase 3 first posted: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., SYN008 + Omalizumab for injection (NCT04944602)
- 2021-05-11Results posted on the registry: Hoffmann-La Roche, Omalizumab + Placebo (NCT03478930)
- 2021-04-20Results posted on the registry: Johns Hopkins University, Omalizumab (NCT03111628)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision